Download
s12931-021-01857-y.pdf 1,26MB
WeightNameValue
1000 Titel
  • Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
1000 Autor/in
  1. Marijic, Pavo |
  2. Schwarzkopf, Larissa |
  3. Schwettmann, Lars |
  4. Ruhnke, Thomas |
  5. Trudzinski, Franziska |
  6. Kreuter, Michael |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-10-19
1000 Erschienen in
1000 Quellenangabe
  • 22(1):268
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12931-021-01857-y |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527681/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Two antifibrotic drugs, pirfenidone and nintedanib, are licensed for the treatment of patients with idiopathic pulmonary fibrosis (IPF). However, there is neither evidence from prospective data nor a guideline recommendation, which drug should be preferred over the other. This study aimed to compare pirfenidone and nintedanib-treated patients regarding all-cause mortality, all-cause and respiratory-related hospitalizations, and overall as well as respiratory-related health care costs borne by the Statutory Health Insurance (SHI).!##!Methods!#!A retrospective cohort study with SHI data was performed, including IPF patients treated either with pirfenidone or nintedanib. Stabilized inverse probability of treatment weighting (IPTW) based on propensity scores was applied to adjust for observed covariates. Weighted Cox models were estimated to analyze mortality and hospitalization. Weighted cost differences with bootstrapped 95% confidence intervals (CI) were applied for cost analysis.!##!Results!#!We compared 840 patients treated with pirfenidone and 713 patients treated with nintedanib. Both groups were similar regarding two-year all-cause mortality (HR: 0.90 95% CI: 0.76; 1.07), one-year all cause (HR: 1.09, 95% CI: 0.95; 1.25) and respiratory-related hospitalization (HR: 0.89, 95% CI: 0.72; 1.08). No significant differences were observed regarding total (€- 807, 95% CI: €- 2977; €1220) and respiratory-related (€- 1282, 95% CI: €- 3423; €534) costs.!##!Conclusion!#!Our analyses suggest that the patient-related outcomes mortality, hospitalization, and costs do not differ between the two currently available antifibrotic drugs pirfenidone and nintedanib. Hence, the decision on treatment with pirfenidone versus treatment with nintedanib ought to be made case-by-case taking clinical characteristics, comorbidities, comedications, individual risk of side effects, and patients' preferences into account.
1000 Sacherschließung
lokal Idiopathic Pulmonary Fibrosis/drug therapy [MeSH]
lokal Aged, 80 and over [MeSH]
lokal Aged [MeSH]
lokal Hospitalization [MeSH]
lokal Risk Assessment [MeSH]
lokal Antifibrotic Agents/therapeutic use [MeSH]
lokal Idiopathic pulmonary fibrosis
lokal Ambulatory Care/economics [MeSH]
lokal Antifibrotic Agents/adverse effects [MeSH]
lokal Risk Factors [MeSH]
lokal Hospital Costs [MeSH]
lokal Administrative data
lokal Hospitalization
lokal Pyridones/therapeutic use [MeSH]
lokal Drug Costs [MeSH]
lokal Indoles/therapeutic use [MeSH]
lokal Mortality
lokal Male [MeSH]
lokal Indoles/adverse effects [MeSH]
lokal Antifibrotic Agents/economics [MeSH]
lokal Statutory health insurance
lokal Female [MeSH]
lokal Idiopathic Pulmonary Fibrosis/mortality [MeSH]
lokal Humans [MeSH]
lokal Treatment Outcome [MeSH]
lokal Retrospective Studies [MeSH]
lokal Middle Aged [MeSH]
lokal Health care costs
lokal Time Factors [MeSH]
lokal Indoles/economics [MeSH]
lokal Pyridones/economics [MeSH]
lokal Pyridones/adverse effects [MeSH]
lokal Research
lokal Drugs
lokal Idiopathic Pulmonary Fibrosis/economics [MeSH]
lokal Idiopathic Pulmonary Fibrosis/diagnosis [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-6321-7296|https://frl.publisso.de/adhoc/uri/U2Nod2FyemtvcGYsIExhcmlzc2E=|https://frl.publisso.de/adhoc/uri/U2Nod2V0dG1hbm4sIExhcnM=|https://frl.publisso.de/adhoc/uri/UnVobmtlLCBUaG9tYXM=|https://frl.publisso.de/adhoc/uri/VHJ1ZHppbnNraSwgRnJhbnppc2th|https://frl.publisso.de/adhoc/uri/S3JldXRlciwgTWljaGFlbA==
1000 Hinweis
  • DeepGreen-ID: 8e8b2dcee4df4075bdbf72044a6099da ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6463277.rdf
1000 Erstellt am 2023-11-15T17:39:39.588+0100
1000 Erstellt von 322
1000 beschreibt frl:6463277
1000 Zuletzt bearbeitet 2023-11-30T21:21:36.035+0100
1000 Objekt bearb. Thu Nov 30 21:21:36 CET 2023
1000 Vgl. frl:6463277
1000 Oai Id
  1. oai:frl.publisso.de:frl:6463277 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source